Curcumin - Vascarta
Alternative Names: VAS-101 -Vascarta; Vasceptor®Latest Information Update: 23 Apr 2025
At a glance
- Originator Albert Einstein College of Medicine
- Developer Vascarta
- Class Analgesics; Anti-ischaemics; Antianaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action CCR2 receptor antagonists; Chemokine CCL 5 inhibitors; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; HIV integrase inhibitors; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoarthritis; Sickle cell anaemia
- Preclinical Sarcopenia